Citeline Features Endo Experts’ Insights on the Future of Biopharma in “Scrip Asks” Series
Health & Patients Research & Innovation
At Endo, we are driven by a passion for bold innovation, inspired by the complexities and challenges within the healthcare system. Our commitment to understanding the needs of those we serve empowers us to work toward improving patient journeys in meaningful ways.
Citeline highlighted this dedication in its 2025 series, “Scrip Asks... What Does 2025 Hold For Biopharma?”, featuring insights from two of our leaders—Patrick Barry, President, Global Commercial Operations, and Justin Mattice, Senior Vice President & General Manager of Branded Specialty Marketing. They detailed Endo’s advancements in artificial intelligence (AI) and nonsurgical interventions, both in service of supporting quality patient care.
Uncovering Opportunities in Patient Engagement with AI
Endo is integrating AI capabilities into our patient engagement to improve experiences. We have developed AI capabilities to analyze data from patient call centers, helping us to review massive amounts of feedback to identify issues quickly and early. With this insight, we can swiftly address challenges and implement targeted solutions that lead to a better patient journey.
“Artificial intelligence offers vast potential in the biopharma industry to accelerate advances for patients and improve their care experience. … This time saved from engagement to insight is essential for our industry as we work every day to help people live their best life.” – Justin Mattice
Read more in the Scrip Asks article: “Part 4: Artificial Intelligence and Data Science.”
Nonsurgical Advancements for Patient Choice
As the population ages and as people maintain active lifestyles in all their decades, Endo aims to support individuals in achieving those goals. Nonsurgical approaches offer patients the opportunity to preserve their activities and lifestyles while avoiding the complexities of surgery.
With these nonsurgical options, we create pathways for patient choice when it comes to developing the treatment path that’s right for them, taking into consideration downtime, cost, time commitment, and other factors.
“I’m energized as I see advancements in nonsurgical interventions for orthopedics and musculoskeletal conditions that not only give patients alternatives to surgery but can also help them maintain the lifestyles they want. ... By investing in nonsurgical approaches, we can offer treatments to patients that can potentially help improve recovery time and improve overall healthcare costs, while maximizing patient outcomes.” – Patrick Barry
Read more in the Scrip Asks article: “Part 6: Therapeutic Area Advances.”
Biopharma holds the promise to transform healthcare by embracing innovation and keeping patients at the heart of everything we do. Through Endo's work across the industry, we can improve the patient experience and support better outcomes.
